Multiple Tumor Types

Viewing Page 2 of 6 | Showing Results 11 - 20 of 54

ZWI-ZW25-101 (anti-Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Patients will receive intratumoral (IT) NKTR-262 in 3-week treatment cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following A Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Evaluate pharmacokinetics of the study drug. Evaluate the safety of the study drug, niraparib, in cancer patients with moderate hepatic impairment.

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A PHASE 1/2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTITUMOR ACTIVITY OF GEN-009 ADJUVANTED VACCINE IN ADULT PATIENTS WITH SELECTED SOLID TUMORS

In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of...

Przemyslaw Twardowski
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered prior to Definitive Surgical Resection in Patients with Head and Neck Squamous Cell Carcinoma or Melanoma (AZ ESR-16-12559)

This clinical trial is the first to evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Procurement and Research Evaluation of Human Blood and Tissues for Detection of Occult Malignancies Using the Polymerase Chain Reaction (PCR) and Proteomics

Patient specimens (archived paraffin-embedded and frozen specimens and blood/body fluid samples) will be accrued from patients at John Wayne Cancer...

Dave Hoon, Ph.D
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)
Viewing Page 2 of 6 | Showing Results 11 - 20 of 54